Company profile

Mark J. Alles
Incorporated in
Fiscal year end
IRS number

CELG stock data



31 Oct 19
3 Jun 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 4.52B 4.4B 4.03B 4.04B
Net income 1.07B
Diluted EPS 2.32 2.16 2.14 1.5
Net profit margin 26.58%
Operating income 2.26B 2.11B 1.71B 1.81B
Net change in cash 2.39B 1.78B 1.2B 1.75B
Cash on hand 9.6B 7.21B 5.43B 4.23B
Cost of revenue 167M 151M 140M 169M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 15.28B 13B 11.23B 9.26B
Net income 4.05B 2.94B 2B 1.6B
Diluted EPS 5.51 3.64 2.49 1.94
Net profit margin 26.48% 22.61% 17.80% 17.31%
Operating income 5.19B 4.71B 3.17B 2.26B
Net change in cash -2.78B 843M 1.29B 758M
Cash on hand 4.23B 7.01B 6.17B 4.88B
Cost of revenue 587M 461M 438M 420M

Financial data from Celgene earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
20 Nov 19 Nadim Ahmed Stock Option Common Stock Sale back to company Dispose D 117.18 5,000 585.9K 0
20 Nov 19 Rupert Vessey Common Stock Sale back to company Dispose D 0 613 0 0
20 Nov 19 Rupert Vessey Common Stock Grant Aquire A 0 24,209 0 60,927
20 Nov 19 Rupert Vessey Common Stock Grant Aquire A 0 13,906 0 36,718
20 Nov 19 Rupert Vessey Common Stock Grant Aquire A 0 8,634 0 22,812
20 Nov 19 Rupert Vessey RSU Common Stock Sale back to company Dispose D 0 37,660 0 0
20 Nov 19 Rupert Vessey RSU Common Stock Sale back to company Dispose D 0 5,794 0 0
20 Nov 19 Rupert Vessey RSU Common Stock Sale back to company Dispose D 0 9,271 0 0
20 Nov 19 Rupert Vessey RSU Common Stock Sale back to company Dispose D 0 3,120 0 0
20 Nov 19 Rupert Vessey RSU Common Stock Sale back to company Dispose D 0 5,756 0 0
13F holders
Current Prev Q Change
Total holders 8 12 -33.3%
Opened positions 7 1 +600.0%
Closed positions 11 1225 -99.1%
Increased positions 0 1 -100.0%
Reduced positions 0 2 -100.0%
13F shares
Current Prev Q Change
Total value 14.84M 1.32B -98.9%
Total shares 137.26K 436.07K -68.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Central Bank & Trust 47.14K $4.36M NEW
Osborn Williams & Donohoe 40.41K $3.81M NEW
Thomasville National Bank 38.16K $3.79M NEW
Headinvest 11.3K $1.07M NEW
Perennial Advisors 235 $27K NEW
Elmwood Wealth Management 20 $1.78M NEW
Proequities 0 $0
IFP Advisors 0 $0
Largest transactions
Shares Bought/sold Change
Wedgewood Partners 0 -393.97K EXIT
Central Bank & Trust 47.14K +47.14K NEW
Osborn Williams & Donohoe 40.41K +40.41K NEW
Thomasville National Bank 38.16K +38.16K NEW
Howard Capital Management 0 -16.84K EXIT
Factorial Partners 0 -12.9K EXIT
Headinvest 11.3K +11.3K NEW
First Citizens Bank & Trust 0 -3.45K EXIT
Private Capital Management 0 -3.3K EXIT
Clarus Wealth Advisors 0 -2.04K EXIT

Financial report summary

  • Our operating results may be subject to significant fluctuations.
  • Our future commercial success depends on gaining regulatory approval for products in development, and obtaining approvals for our current products for additional indications.
  • If we fail to comply with laws or government regulations or policies our business could be adversely affected.
  • Sales of our products will be significantly reduced if access to and reimbursement for our products by governmental and other third-party payers are reduced or terminated.
  • Federal and state legislation may affect our pricing policies and government reimbursement of our products which may adversely impact our revenues and profitability.
  • Our ability to sell our products to hospitals in the United States depends in part on our relationships with group purchasing organizations.
  • Our products may face competition from lower cost generic or follow-on products.
  • Certain novel approaches to the treatment of diseases, such as chimeric antigen receptor (CAR) T cell therapy, may present significant challenges and risks for us.
  • Our business operates in an extremely competitive environment.
  • A decline in general economic conditions would adversely affect our results of operations.
  • We may be required to modify our business practices, pay fines and significant expenses or experience other losses due to governmental investigations or other enforcement activities.
  • The development of new biopharmaceutical products involves a lengthy and complex process and we may be unable to commercialize any of the products we are currently developing.
  • Disruptions of our manufacturing and distribution operations could significantly interrupt our production and distribution capabilities.
  • The consolidation of drug wholesalers and other wholesaler actions could increase competitive and pricing pressures.
  • Risks from the improper conduct of employees, agents, contractors or collaborators could adversely affect our business or reputation.
  • We are subject to a variety of risks related to the conduct and expansion of our business internationally, particularly in emerging markets.
  • We may not realize the anticipated benefits of acquisitions and strategic initiatives.
  • We may not be able to continue to attract and retain highly qualified managerial, scientific, manufacturing and commercial talent.
  • Risks associated with using hazardous materials in our business could subject us to significant liability.
  • We are subject to various legal proceedings, claims and investigative demands in the ordinary course of our business, the ultimate outcome of which may result in significant expense, payments and penalties.
  • Product liability claims could adversely affect our business, results of operations and financial condition.
  • Changes in our effective income tax rate could adversely affect our results of operations.
  • Currency fluctuations and changes in exchange rates could adversely affect our revenue growth, increase our costs and cause our profitability to decline.
  • We may experience an adverse market reaction if we are unable to meet our financial reporting obligations.
  • Impairment charges or write downs in our books and changes in accounting standards could have a significant adverse effect on our results of operations and financial condition.
  • The price of our common stock may fluctuate significantly.
  • Our business would be adversely affected if we are unable to service our debt obligations.
  • A breakdown or breach of our information technology systems and cyber security efforts could subject us to liability, reputational damage or interrupt the operation of our business.
  • The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.
  • We have certain charter and by-law provisions that may deter a third party from acquiring us and may impede the stockholders’ ability to remove and replace our management or board of directors.
  • In addition to the risks relating to our common stock, holders of our CVRs are subject to additional risks.
  • While the merger is pending, we are subject to business uncertainties and contractual restrictions that could materially adversely affect our operating results, financial position and/or cash flows or result in a loss of employees, customers, collaborators or suppliers.
  • Lawsuits have been filed against us and Bristol-Myers Squibb and other lawsuits may be filed against us and/or Bristol-Myers Squibb challenging the transactions contemplated by the merger agreement. An adverse ruling in any such lawsuit may delay or prevent the proposed acquisition from being completed.
  • We may have difficulty attracting, motivating and retaining executives and other key employees in light of the merger.
Content analysis ?
H.S. freshman Avg
New words: antibody, apremilast, banc, checkpoint, CMA, deadline, divest, en, Inducible, INREBIC, Jounce, macrophage, MF, NaN, pool, QUAZAR, retroactive, SPARC, TSA
Removed: ADR, argued, breast, certify, content, create, curiae, denying, dispute, entity, exact, implemented, interlocutory, led, outpatient, prohibition, protecting, resolution, Sherman, submission, Synthon, thirteen


Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
2 Jun 20
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
2 Jun 20
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof.
Antiproliferative Compounds and Methods of Use Thereof
28 May 20
Compounds of formula I for treating, preventing or managing cancer are disclosed.
Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
19 May 20
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Combination therapy for treating malignancies
19 May 20
Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.